Ischaemic heart disease Circulatory System Ischaemic heart disease
Conditions
Interventions
In both IHD and healthy control groups, participants were stratified into tertiles of homocysteine concentration (from the screening blood sample). Subjects in each stratum were then randomised to rec
Sponsors
University of Ulster (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Male and female, any age 2. IHD Patients: 2.1. Proven myocardial infarction more than three months previously 2.2. IHD on coronary angiography 2.3. A clinical diagnosis of angina confirmed by electrocardiogram (ECG) 3. Control subjects: healthy subjects age- and sex-matched with the IHD group from the local community
Exclusion criteria
Exclusion criteria: 1. IHD patients: 1.1. History of diabetes 1.2. Hepatic or renal disease 1.3. Haematological disorders 1.4. Use of B-vitamin supplements or use of medication known to interfere with folate metabolism 2. Healthy controls in addition had no history of CVD
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma homocysteine, measured at baseline, 6 weeks and 12 weeks in a subset, and at 26 weeks. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Serum folate, measured at baseline and at 26 weeks 2. Erythrocyte glutathione reductase activity coefficient (EGRac): an indicator of riboflavin status), measured at baseline 2. Plasma pyridoxal phosphate: an indicator of vitamin B6 status, measured at baseline 3. Serum vitamin B12, measured at baseline | — |
Countries
United Kingdom
Outcome results
None listed